These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 5012351)

  • 41. [Intravenous and oral treatment with amantadine sulfate in Parkinson disease].
    Brenner M; Haass A; Jacobi P; Schimrigk K
    Nervenarzt; 1988 Mar; 59(3):180-4. PubMed ID: 3374720
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Observations on the effect of amantadine hydrochloride in the treatment of Parkinsonism.
    Schwieger AC; Jenkins AC
    Med J Aust; 1970 Oct; 2(14):630-2. PubMed ID: 5477806
    [No Abstract]   [Full Text] [Related]  

  • 43. Administration of amandine to patients on optimum L-dopa dosage.
    Fehling C
    Acta Neurol Scand Suppl; 1972; 51():119-20. PubMed ID: 4514335
    [No Abstract]   [Full Text] [Related]  

  • 44. [Principles for amantadine therapy in parkinsonism].
    Gilland O
    Lakartidningen; 1972 Nov; 69(46):5343-5. PubMed ID: 4650743
    [No Abstract]   [Full Text] [Related]  

  • 45. The management of parkinsonism.
    N Z Med J; 1971 Jul; 74(470):36-7. PubMed ID: 5289750
    [No Abstract]   [Full Text] [Related]  

  • 46. [Amantadine and L-Dopa in the treatment of parkinsonian syndromes].
    Kluzer G; Lampo B
    Minerva Med; 1971 Oct; 62(82):4013-4. PubMed ID: 5125067
    [No Abstract]   [Full Text] [Related]  

  • 47. [Conservative therapy in the Parkinson syndrome].
    Birkmayer W
    Wien Med Wochenschr; 1971 Nov; 121(46):827-9. PubMed ID: 5138823
    [No Abstract]   [Full Text] [Related]  

  • 48. [Combined therapy of parkinsonism using amantadine].
    Umbach W; Oppel F
    Munch Med Wochenschr; 1973 Apr; 115(14):604-7. PubMed ID: 4740225
    [No Abstract]   [Full Text] [Related]  

  • 49. [Amantadine and L-Dopa in the treatment of parkinsonian syndromes and their implications for rehabilitation].
    Raspa EG; Paciaroni E; Saccomanno G
    Minerva Med; 1971 Oct; 62(82):4031-5. PubMed ID: 5125073
    [No Abstract]   [Full Text] [Related]  

  • 50. [Clinical results of the intravenous administration of amantadine in patients with parkinsonism].
    Caliri F; Di Rosa AE; Meduri M; Megna G; Musolino R; Scuderi D
    Minerva Med; 1971 Oct; 62(82):3994-6. PubMed ID: 5125062
    [No Abstract]   [Full Text] [Related]  

  • 51. [Amantadine for parkinsonism].
    Flatberg P
    Tidsskr Nor Laegeforen; 1970 May; 90(10):1101-2. PubMed ID: 5450047
    [No Abstract]   [Full Text] [Related]  

  • 52. [Electrophysiological findings during treatment of the parkinsonian syndrome with amantadine].
    Di Perri R; Livrea P; Messina C; Puca FM; Tomasello F
    Minerva Med; 1971 Oct; 62(82):3997-9. PubMed ID: 4331007
    [No Abstract]   [Full Text] [Related]  

  • 53. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
    da Silva-Júnior FP; Braga-Neto P; Sueli Monte F; de Bruin VM
    Parkinsonism Relat Disord; 2005 Nov; 11(7):449-52. PubMed ID: 16154788
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Controlled trial of amantadine hydrochloride in Parkinson's disease.
    Jorgensen PB; Bergin JD; Haas L; Cuningham JA; Morah DD; Pollock M; Robinson RG; Spears GF
    N Z Med J; 1971 May; 73(468):263-7. PubMed ID: 4932146
    [No Abstract]   [Full Text] [Related]  

  • 55. Amantadine in Parkinson's disease. Review of more than two years' experience.
    Schwab RS; Poskanzer DC; England AC; Young RR
    JAMA; 1972 Nov; 222(7):792-5. PubMed ID: 4677928
    [No Abstract]   [Full Text] [Related]  

  • 56. [Treatment of the parkinsonian syndrome with L-dopa and amantadine].
    Pendefunda GH; Pollingher B; Stefanache F; Gavril A; Oprişan C; Merling M; Nemţeanu E; Ciuntu M; Koropitzer I
    Neurol Psihiatr Neurochir; 1973; 18(6):559-68. PubMed ID: 4790488
    [No Abstract]   [Full Text] [Related]  

  • 57. [Use of the Soviet preparation midantan in the treatment of the Parkinsonian syndrome].
    Balunov OA; Bazhin EF; Morozova ES; Fedotenkova TN
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1974; 74(8):1178-81. PubMed ID: 4417237
    [No Abstract]   [Full Text] [Related]  

  • 58. Differentiation of tardive dyskinesias and drug-induced Parkinsonism.
    N Engl J Med; 1971 Jun; 284(24):1382-4. PubMed ID: 5576464
    [No Abstract]   [Full Text] [Related]  

  • 59. [Treatment of parkinsonism with viregyt (amantadine)].
    Pryszmont M; Jankowicz E; Eljasz L; Slizewski M; Wiśniewska Z
    Wiad Lek; 1974 Aug; 27(15):1371-5. PubMed ID: 4418066
    [No Abstract]   [Full Text] [Related]  

  • 60. [Prolonged treatment of Parkinson's disease with amantadine and L-Dopa].
    Fieschi C; Casacchia M; Nardini M; Reitano N
    Minerva Med; 1971 Oct; 62(82):4040-2. PubMed ID: 5125075
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.